17 research outputs found
Advanced perfusion quantification methods for dynamic PET and MRI data modelling
The functionality of tissues is guaranteed by the capillaries, which supply the microvascular
network providing a considerable surface area for exchanges between blood and tissues.
Microcirculation is affected by any pathological condition and any change in the blood supply
can be used as a biomarker for the diagnosis of lesions and the optimization of the treatment.
Nowadays, a number of techniques for the study of perfusion in vivo and in vitro are
available. Among the several imaging modalities developed for the study of microcirculation,
the analysis of the tissue kinetics of intravenously injected contrast agents or tracers is the
most widely used technique. Tissue kinetics can be studied using different modalities: the
positive enhancement of the signal in the computed tomography and in the ultrasound
dynamic contrast enhancement imaging; T1-weighted MRI or the negative enhancement of
T2* weighted MRI signal for the dynamic susceptibility contrast imaging or, finally, the
uptake of radiolabelled tracers in dynamic PET imaging. Here we will focus on the perfusion
quantification of dynamic PET and MRI data. The kinetics of the contrast agent (or the tracer)
can be analysed visually, to define qualitative criteria but, traditionally, quantitative
physiological parameters are extracted with the implementation of mathematical models.
Serial measurements of the concentration of the tracer (or of the contrast agent) in the tissue
of interest, together with the knowledge of an arterial input function, are necessary for the
calculation of blood flow or perfusion rates from the wash-in and/or wash-out kinetic rate
constants. The results depend on the acquisition conditions (type of imaging device, imaging
mode, frequency and total duration of the acquisition), the type of contrast agent or tracer
used, the data pre-processing (motion correction, attenuation correction, correction of the
signal into concentration) and the data analysis method.
As for the MRI, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a
non-invasive imaging technique that can be used to measure properties of tissue
microvasculature. It is sensitive to differences in blood volume and vascular permeability that
can be associated with tumour angiogenesis. DCE-MRI has been investigated for a range of
clinical oncologic applications (breast, prostate, cervix, liver, lung, and rectum) including
cancer detection, diagnosis, staging, and assessment of treatment response. Tumour
microvascular measurements by DCE-MRI have been found to correlate with prognostic
factors (such as tumour grade, microvessel density, and vascular endothelial growth factor
expression) and with recurrence and survival outcomes. Furthermore, DCE-MRI changes
measured during treatment have been shown to correlate with outcome, suggesting a role as
a predictive marker. The accuracy of DCE-MRI relies on the ability to model the
pharmacokinetics of an injected contrast agent using the signal intensity changes on
sequential magnetic resonance images. DCE-MRI data are usually quantified with the
application of the pharmacokinetic two-compartment Tofts model (also known as the
standard model), which represents the system with the plasma and tissue (extravascular
extracellular space) compartments and with the contrast reagent exchange rates between
them. This model assumes a negligible contribution from the vascular space and considers
the system in, what-is-known as, the fast exchange limit, assuming infinitely fast
transcytolemmal water exchange kinetics. In general, the number, as well as any assumption
about the compartments, depends on the properties of the contrast agent used (mainly
gadolinium) together with the tissue physiology or pathology studied. For this reason, the
choice of the model is crucial in the analysis of DCE-MRI data. The value of PET in clinical oncology has been demonstrated with studies in a variety of
cancers including colorectal carcinomas, lung tumours, head and neck tumours, primary and
metastatic brain tumours, breast carcinoma, lymphoma, melanoma, bone cancers, and other
soft-tissue cancers. PET studies of tumours can be performed for several reasons including
the quantification of tumour perfusion, the evaluation of tumour metabolism, the tracing of
radiolabelled cytostatic agents. In particular, the kinetic analysis of PET imaging has showed,
in the past few years, an increasing value in tumour diagnosis, as well as in tumour therapy,
through providing additional indicative parameters. Many authors have showed the benefit
of kinetic analysis of anticancer drugs after labelling with radionuclide in measuring the
specific therapeutic effect bringing to light the feasibility of applying the kinetic analysis to
the dynamic acquisition. Quantification methods can involve visual analysis together with
compartmental modelling and can be applied to a wide range of different tracers. The
increased glycolysis in the most malignancies makes 18F-FDG-PET the most common
diagnostic method used in tumour imaging. But, PET metabolic alteration in the target tissue
can depend by many other factors. For example, most types of cancer are characterized by
increased choline transport and by the overexpression of choline kinase in highly proliferating
cells in response to enhanced demand of phosphatidylcholine (prostate, breast, lung, ovarian
and colon cancers). This effect can be diagnosed with choline-based tracers as the 18Ffluoromethylcholine
(18F-FCH), or the even more stable 18F-D4-Choline. Cellular
proliferation is also imaged with 18F-fluorothymidine (FLT), which is trapped within the
cytosol after being mono phosphorylated by thymidine kinase-1 (TK1), a principal enzyme
in the salvage pathway of DNA synthesis. 18F-FLT has been found to be useful for noninvasive
assessment of the proliferation rate of several types of cancer and showed high
reproducibility and accuracy in breast and lung cancer tumours.
The aim of this thesis is the perfusion quantification of dynamic PET and MRI data of patients
with lung, brain, liver, prostate and breast lesions with the application of advanced models.
This study covers a wide range of imaging methods and applications, presenting a novel
combination of MRI-based perfusion measures with PET kinetic modelling parameters in
oncology. It assesses the applicability and stability of perfusion quantification methods,
which are not currently used in the routine clinical practice.
The main achievements of this work include: 1) the assessment of the stability of perfusion
quantification of D4-Choline and 18F-FLT dynamic PET data in lung and liver lesions,
respectively (first applications in the literature); 2) the development of a model selection in
the analysis of DCE-MRI data of primary brain tumours (first application of the extended
shutter speed model); 3) the multiparametric analysis of PET and MRI derived perfusion
measurements of primary brain tumour and breast cancer together with the integration of
immuohistochemical markers in the prediction of breast cancer subtype (analysis of data
acquired on the hybrid PET/MRI scanner).
The thesis is structured as follows:
- Chapter 1 is an introductive chapter on cancer biology. Basic concepts, including the causes
of cancer, cancer hallmarks, available cancer treatments, are described in this first chapter.
Furthermore, there are basic concepts of brain, breast, prostate and lung cancers (which are
the lesions that have been analysed in this work). - Chapter 2 is about Positron Emission Tomography. After a brief introduction on the basics
of PET imaging, together with data acquisition and reconstruction methods, the chapter
focuses on PET in the clinical settings. In particular, it shows the quantification techniques
of static and dynamic PET data and my results of the application of graphical methods,
spectral analysis and compartmental models on dynamic 18F-FDG, 18F-FLT and 18F-D4-
Choline PET data of patients with breast, lung cancer and hepatocellular carcinoma.
- Chapter 3 is about Magnetic Resonance Imaging. After a brief introduction on the basics of
MRI, the chapter focuses on the quantification of perfusion weighted MRI data. In particular,
it shows the pharmacokinetic models for the quantification of dynamic contrast enhanced
MRI data and my results of the application of the Tofts, the extended Tofts, the shutter speed
and the extended shutter speed models on a dataset of patients with brain glioma.
- Chapter 4 introduces the multiparametric imaging techniques, in particular the combined
PET/CT and the hybrid PET/MRI systems. The last part of the chapter shows the applications
of perfusion quantification techniques on a multiparametric study of breast tumour patients,
who simultaneously underwent DCE-MRI and 18F-FDG PET on a hybrid PET/MRI scanner.
Then the results of a predictive study on the same dataset of breast tumour patients integrated
with immunohistochemical markers. Furthermore, the results of a multiparametric study on
DCE-MRI and 18F-FCM brain data acquired both on a PET/CT scanner and on an MR
scanner, separately. Finally, it will show the application of kinetic analysis in a radiomic
study of patients with prostate cancer
Radiogenomics in non-small-cell lung cancer
Ο μη μικροκυτταρικός καρκίνος του πνεύμονα είναι ο πιο συχνά συναντώμενος υποτύπος καρκίνου του πνεύμονα, ο οποίος αποτελείται από ένα φάσμα υποτύπων. Το NSCLC είναι ένας θανατηφόρος, ετερογενής συμπαγής όγκος με μια εκτεταμένη σειρά μοριακών χαρακτηριστικών. Η πάθηση έχει γίνει ένα αξιοσημείωτο παράδειγμα ιατρικής ακριβείας καθώς το ενδιαφέρον για το θέμα συνεχίζει να επεκτείνεται. Ο απώτερος στόχος της τρέχουσας έρευνας είναι να χρησιμοποιήσει συγκεκριμένα γονίδια ως βιοδείκτες για την πρόγνωση, την έγκαιρη διάγνωση και την εξατομικευμένη θεραπεία, τα οποία διευκολύνονται από τη χρήση εξελισσόμενων τεχνικών αλληλούχισης επόμενης γενιάς που επιτρέπουν την ταυτόχρονη ανίχνευση μεγάλου αριθμού γενετικές ανωμαλίες. Γνωστές μεταλλάξεις ενός αριθμού γονιδίων, όπως τα EGFR, ALK και KRAS, επηρεάζουν ήδη τις αποφάσεις θεραπείας και νέα βασικά γονίδια και μοριακές υπογραφές διερευνώνται για την προγνωστική τους αξία καθώς και για την πιθανή συμβολή τους στην ανοσοθεραπεία και τη θεραπεία της υποτροπής στην αντίσταση στις υπάρχουσες θεραπείες. Οι τύποι δειγμάτων που χρησιμοποιούνται για μελέτες NGS, όπως αναρροφήσεις με λεπτή βελόνα, ιστός ενσωματωμένος σε παραφίνη σταθεροποιημένος με φορμαλίνη και DNA χωρίς κύτταρα, έχουν ο καθένας τα δικά του πλεονεκτήματα και μειονεκτήματα που πρέπει να ληφθούν υπόψηNon-small cell lung cancer is the most often encountered subtype of lung cancer, which consists of a spectrum of subtypes. NSCLC is a lethal, heterogeneous solid tumor with an extensive array of molecular features. The condition has become a notable example of precision medicine as interest in the topic continues to expand. The ultimate goal of the current research is to use specific genes as biomarkers for its prognosis, timely diagnosis, and personalized therapy, all of which are facilitated by the use of evolving next-generation sequencing techniques that permit the simultaneous detection of a large number of genetic abnormalities. Known mutations of a number of genes, such as EGFR, ALK, and KRAS, already influence treatment decisions, and new key genes and molecular signatures are being investigated for their prognostic value as well as their potential contribution to immunotherapy and the treatment of recurrence due to resistance to existing therapies. The sample types utilized for NGS studies, such as fine-needle aspirates, formalin-fixed paraffin-embedded tissue, and cell-free DNA, each have their own advantages and disadvantages that must be taken into accoun
Advanced machine learning methods for oncological image analysis
Cancer is a major public health problem, accounting for an estimated 10 million deaths worldwide in 2020 alone. Rapid advances in the field of image acquisition and hardware development over the past three decades have resulted in the development of modern medical imaging modalities that can capture high-resolution anatomical, physiological, functional, and metabolic quantitative information from cancerous organs. Therefore, the applications of medical imaging have become increasingly crucial in the clinical routines of oncology, providing screening, diagnosis, treatment monitoring, and non/minimally- invasive evaluation of disease prognosis. The essential need for medical images, however, has resulted in the acquisition of a tremendous number of imaging scans. Considering the growing role of medical imaging data on one side and the challenges of manually examining such an abundance of data on the other side, the development of computerized tools to automatically or semi-automatically examine the image data has attracted considerable interest. Hence, a variety of machine learning tools have been developed for oncological image analysis, aiming to assist clinicians with repetitive tasks in their workflow.
This thesis aims to contribute to the field of oncological image analysis by proposing new ways of quantifying tumor characteristics from medical image data. Specifically, this thesis consists of six studies, the first two of which focus on introducing novel methods for tumor segmentation. The last four studies aim to develop quantitative imaging biomarkers for cancer diagnosis and prognosis.
The main objective of Study I is to develop a deep learning pipeline capable of capturing the appearance of lung pathologies, including lung tumors, and integrating this pipeline into the segmentation networks to leverage the segmentation accuracy. The proposed pipeline was tested on several comprehensive datasets, and the numerical quantifications show the superiority of the proposed prior-aware DL framework compared to the state of the art. Study II aims to address a crucial challenge faced by supervised segmentation models: dependency on the large-scale labeled dataset. In this study, an unsupervised segmentation approach is proposed based on the concept of image inpainting to segment lung and head- neck tumors in images from single and multiple modalities. The proposed autoinpainting pipeline shows great potential in synthesizing high-quality tumor-free images and outperforms a family of well-established unsupervised models in terms of segmentation accuracy.
Studies III and IV aim to automatically discriminate the benign from the malignant pulmonary nodules by analyzing the low-dose computed tomography (LDCT) scans. In Study III, a dual-pathway deep classification framework is proposed to simultaneously take into account the local intra-nodule heterogeneities and the global contextual information. Study IV seeks to compare the discriminative power of a series of carefully selected conventional radiomics methods, end-to-end Deep Learning (DL) models, and deep features-based radiomics analysis on the same dataset. The numerical analyses show the potential of fusing the learned deep features into radiomic features for boosting the classification power.
Study V focuses on the early assessment of lung tumor response to the applied treatments by proposing a novel feature set that can be interpreted physiologically. This feature set was employed to quantify the changes in the tumor characteristics from longitudinal PET-CT scans in order to predict the overall survival status of the patients two years after the last session of treatments. The discriminative power of the introduced imaging biomarkers was compared against the conventional radiomics, and the quantitative evaluations verified the superiority of the proposed feature set. Whereas Study V focuses on a binary survival prediction task, Study VI addresses the prediction of survival rate in patients diagnosed with lung and head-neck cancer by investigating the potential of spherical convolutional neural networks and comparing their performance against other types of features, including radiomics. While comparable results were achieved in intra- dataset analyses, the proposed spherical-based features show more predictive power in inter-dataset analyses.
In summary, the six studies incorporate different imaging modalities and a wide range of image processing and machine-learning techniques in the methods developed for the quantitative assessment of tumor characteristics and contribute to the essential procedures of cancer diagnosis and prognosis